SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nodality, Inc., an innovative biotechnology company advancing discovery, development and use of transformative therapies across broad therapeutic categories, with a focus on immunology and oncology, including immuno-oncology, announced today the expansion of its patent portfolio with the issuance of U.S. Patent No. 8,815,527, “Methods and Compositions for Detecting the Activation State of Multiple Proteins in Single Cells,” as granted by the U.S. Patent and Trademark Office. The issued patent claims cover systems for determining the activation state of more than one protein in a cell, where the system can utilize any detector, including cytometers and mass spectrometers. The ‘527 patent extends through September 2023 and is exclusively licensed by Nodality from Stanford University.
Help employers find you! Check out all the jobs and post your resume.
